This technology is a diagnostic assay for serologic biomarkers associated with non-celiac gluten/wheat sensitivity (NCGS/NCWS) in patients.
Celiac disease is a common autoimmune disorder that is characterized by an immune response to ingested wheat gluten. Some individuals, however, experience a range of symptoms in response to ingestion of wheat and related cereals, yet lack the characteristic serologic, histologic, or genetic markers of celiac disease. The terms non-celiac gluten sensitivity (NCGS) or non-celiac wheat sensitivity (NCWS) are generally used to refer to this condition, which is currently understood as the collection of symptoms in response to ingestion of gluten-containing foods. Currently, the pathogenesis of NCGS is not well understood, and there remains a need for biological biomarkers to aid in the diagnostics and monitoring of this condition in patients.
This technology is a set of biomarkers that can be used to screen patients for NCGS/NCWS. This diagnostic method involves determining the levels of a combination of select markers found to be associated with NCGS/NCWS in a patient’s blood that may include soluble CD14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2) as indicators of NCGS/NCWS. As such, this technology provides not only a powerful diagnostic tool, but also an effective method for monitoring treatment of this condition.
This technology has been validated using serum from symptomatic individuals where wheat, rye, and barley intake were controlled.
IR CU16173
Licensing Contact: Jerry Kokoshka